[go: up one dir, main page]

MX9700270A - Composicion que contiene acidos nucleicos, preparacion y utilizacion. - Google Patents

Composicion que contiene acidos nucleicos, preparacion y utilizacion.

Info

Publication number
MX9700270A
MX9700270A MX9700270A MX9700270A MX9700270A MX 9700270 A MX9700270 A MX 9700270A MX 9700270 A MX9700270 A MX 9700270A MX 9700270 A MX9700270 A MX 9700270A MX 9700270 A MX9700270 A MX 9700270A
Authority
MX
Mexico
Prior art keywords
nucleic acid
preparation
same
containing composition
acid containing
Prior art date
Application number
MX9700270A
Other languages
English (en)
Inventor
Jean-Paul Behr
Barbara Demeneix
Franck Lezoualch
Mojgan Mergny
Daniel Scherman
Otmane Boussif
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9465376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9700270(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of MX9700270A publication Critical patent/MX9700270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

La presente invencion se refiere a las composiciones que comprenden al menos un ácido nucleico y un polímero cationico, y a su utilizacion en terapia génica, principalmente para la transferencia in vivo de ácidos nucleicos.
MX9700270A 1994-07-13 1995-07-07 Composicion que contiene acidos nucleicos, preparacion y utilizacion. MX9700270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9408735A FR2722506B1 (fr) 1994-07-13 1994-07-13 Composition contenant des acides nucleiques, preparation et utilisations
PCT/FR1995/000914 WO1996002655A1 (fr) 1994-07-13 1995-07-07 Composition contenant des acides nucleiques, preparation et utilisations

Publications (1)

Publication Number Publication Date
MX9700270A true MX9700270A (es) 1997-05-31

Family

ID=9465376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700270A MX9700270A (es) 1994-07-13 1995-07-07 Composicion que contiene acidos nucleicos, preparacion y utilizacion.

Country Status (18)

Country Link
US (1) US6013240A (es)
EP (1) EP0770140B1 (es)
JP (1) JP4275728B2 (es)
KR (1) KR100424802B1 (es)
AT (1) ATE367448T1 (es)
AU (1) AU2930795A (es)
CA (1) CA2194797C (es)
DE (1) DE69535540T9 (es)
DK (1) DK0770140T3 (es)
ES (1) ES2290952T3 (es)
FI (1) FI119738B (es)
FR (1) FR2722506B1 (es)
IL (1) IL114566A (es)
MX (1) MX9700270A (es)
NO (1) NO323110B1 (es)
PT (1) PT770140E (es)
WO (1) WO1996002655A1 (es)
ZA (1) ZA955849B (es)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
AU723163B2 (en) * 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
DE59707744D1 (de) * 1996-10-23 2002-08-22 Sueddeutsche Kalkstickstoff Verfahren zur herstellung von biologisch aktiven polymernanopartikel-nucleinsäure-konjugaten
US6071533A (en) * 1996-11-12 2000-06-06 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6884430B1 (en) 1997-02-10 2005-04-26 Aventis Pharma S.A. Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
CA2280997C (en) * 1997-03-11 2013-05-28 Perry B. Hackett Dna-based transposon system for the introduction of nucleic acid into dna of a cell
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
DE19726186A1 (de) * 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
BR9813202B1 (pt) 1997-09-15 2011-11-01 complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes.
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
DE19743135A1 (de) * 1997-09-30 1999-04-01 Hoechst Marion Roussel De Gmbh Biologisch verträgliche niedermolekular Polyethylenimine
CA2335460A1 (en) * 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US6562371B1 (en) * 1998-11-02 2003-05-13 Terumo Kabushiki Kaisha Liposomes
US7160682B2 (en) * 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
JP2002541125A (ja) * 1999-04-02 2002-12-03 リサーチ ディベロップメント ファンデーション エアロゾル送達のためのポリエチレンイミン：ｄｎａ製剤
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
EP1156832A1 (en) 1999-12-28 2001-11-28 Transgene S.A. Use of lithium (li?+ ) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
CA2395636A1 (en) * 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
FR2805271B1 (fr) * 2000-02-18 2002-04-26 Aventis Pharma Sa Procede de preparation de polyalkylenimines fonctionnalises, compositions les contenant et leurs utilisations
FR2813605B1 (fr) * 2000-09-05 2002-10-18 Aventis Pharma Sa Composes acidosensibles, leur preparation et utilisations
EP1317439B1 (fr) * 2000-09-05 2005-12-07 Centelion Composes acidosensibles, leur preparation et utilisations
FR2814370B1 (fr) * 2000-09-22 2004-08-20 Centre Nat Rech Scient Utilisation d'un complexe acide nucleique/pei pour le ciblage de cellules souches du cerveau
CN1479632A (zh) * 2000-10-09 2004-03-03 拜尔公司 用于将核酸导入细胞的复合物
DE10145134A1 (de) * 2000-10-09 2002-05-16 Bayer Ag Komplexe zur Einführung von Nukleinsäuren in Zellen
US20020091242A1 (en) * 2000-10-11 2002-07-11 Michel Bessodes Acid-sensitive compounds, their preparation and uses
JP2004537501A (ja) * 2001-02-01 2004-12-16 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 肺への遺伝子送達のための安定化ポリマーエアロゾル
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US20040234586A1 (en) * 2001-06-11 2004-11-25 Sylvain Meloche Compositions and methods for enhancing nucleic acid transfer into cells
JP4516748B2 (ja) 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
JP2005508396A (ja) * 2001-11-02 2005-03-31 イントラディグム、コーポレイション 核酸送達ビヒクルのための治療方法
EP1466133B1 (en) 2002-01-17 2007-01-03 York Refrigeration APS Submerged evaporator with integrated heat exchanger
US8227432B2 (en) * 2002-04-22 2012-07-24 Regents Of The University Of Minnesota Transposon system and methods of use
US7220400B2 (en) 2002-05-24 2007-05-22 Mirus Bio Corporation Compositions for delivering nucleic acids to cells
AU2003245160B2 (en) 2002-06-28 2009-09-24 Arbutus Biopharma Corporation Method and apparatus for producing liposomes
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
CA2498777C (en) * 2002-09-13 2015-01-13 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
ES2784011T3 (es) 2002-10-16 2020-09-21 Streck Inc Procedimiento y dispositivo para recoger y preservar las células para su análisis
US7153905B2 (en) * 2003-03-21 2006-12-26 The General Hospital Corporation Hyperbranched dendron and methods of synthesis and use thereof
KR101168440B1 (ko) 2003-07-16 2012-07-27 프로티바 바이오쎄라퓨틱스, 인코포레이티드 지질 캡슐화된 간섭 ｒｎａ
AU2004272646B2 (en) 2003-09-15 2011-11-24 Arbutus Biopharma Corporation Polyethyleneglycol-modified lipid compounds and uses thereof
JP2007527240A (ja) * 2004-03-01 2007-09-27 マサチューセッツ インスティテュート オブ テクノロジー アレルギー性鼻炎および喘息のためのＲＮＡｉベースの治療
WO2005089123A2 (en) * 2004-03-04 2005-09-29 Massachusetts Institute Of Technology Therapeutic anti-cancer dna
US20060026699A1 (en) * 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
JP2008504827A (ja) 2004-07-02 2008-02-21 プロチバ バイオセラピューティクス インコーポレイティッド 免疫賦活性ｓｉＲＮＡ分子およびその使用方法
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
AU2008298592A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
EP2047858A1 (en) 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
DE102008016275A1 (de) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
DE102008023913A1 (de) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Verbesserung von Transfektionsergebnissen nicht-viraler Genliefersysteme durch Beeinflussung des angeborenen Immunsystems
DE102007056488A1 (de) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
EP2212425A2 (de) 2007-11-22 2010-08-04 Biontex Laboratories Gmbh Verbesserung von transfektionsergebnissen nicht-viraler genliefersysteme durch beeinflussung des angeborenen immunsystems
GB0724253D0 (en) 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
CA2710713C (en) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
US7687027B2 (en) * 2008-02-27 2010-03-30 Becton, Dickinson And Company Cleaning compositions, methods and materials for reducing nucleic acid contamination
FR2928373B1 (fr) * 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
JP2011516094A (ja) 2008-04-15 2011-05-26 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
US8637315B2 (en) * 2008-05-15 2014-01-28 National Research Council Of Canada Process, vectors and engineered cell lines for enhanced large-scale transfection
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010078194A1 (en) * 2008-12-30 2010-07-08 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
DE102009006606A1 (de) 2009-01-29 2010-08-05 Philipps-Universität Marburg Nicht-virales Transfektionsmittel
EP3778919A1 (en) 2009-02-18 2021-02-17 Streck Inc. Preservation of cell-free nucleic acids
EP2623117A1 (en) 2009-04-30 2013-08-07 Genetic Immunity Kft. Immunogenic nanomedicine composition and preparation and uses thereof
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
EP4089169A1 (en) 2009-10-12 2022-11-16 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
GB0917792D0 (en) * 2009-10-12 2009-11-25 Fermentas Uab Delivery agent
CA2780536C (en) * 2009-11-09 2018-01-02 Streck, Inc. Stabilization of rna in and extracting from intact cells within a blood sample
US9247720B2 (en) 2010-03-24 2016-02-02 Institut National de la Santé et de la Recherche Médicale Primate model from the family cercopithecidae infected by a HBV strain of human genotype
WO2011120953A1 (en) 2010-03-29 2011-10-06 Universite De Strasbourg Polymers for delivering molecules of interest
US20130164380A1 (en) 2010-06-17 2013-06-27 Actogenix Nv Compositions and methods for treating inflammatory conditions
LT3135301T (lt) 2010-06-22 2018-07-10 Onxeo Optimizuota in vivo įvedimo sistema su nukleorūgščių konjugatų endosomas lizuojančiais agentais
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
EP2704740B1 (en) 2011-05-04 2016-10-05 Streck, Inc. Inactivated swine flu virus and methods of preparing it
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance
EP2780456A1 (en) 2011-11-17 2014-09-24 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutic rna switches compositions and methods of use
CN104136605B (zh) 2011-11-24 2018-08-14 吉尼松公司 与工业制药应用相容的可放大的慢病毒载体生产系统
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
JP6208750B2 (ja) * 2012-06-08 2017-10-04 エスリス ゲーエムベーハーｅｔｈｒｉｓ ＧｍｂＨ メッセンジャーｒｎａの肺送達
CN103059295B (zh) * 2012-09-26 2016-01-13 上海交通大学 疏水修饰的聚乙烯亚胺及其作为蛋白质载体的用途
EP4085930A1 (en) 2012-10-05 2022-11-09 BioNTech Delivery Technologies GmbH Hydroxylated polyamine derivatives as transfection reagents for rna
CN112370532B (zh) 2012-10-08 2024-11-01 生物技术传送科技有限责任公司 作为转染试剂的羧化多胺衍生物
DE102012111891A1 (de) * 2012-12-06 2014-06-12 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbesserung der Zielfindungskapazität von Stammzellen
CA2917912C (en) 2013-07-24 2019-09-17 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
WO2015073727A1 (en) 2013-11-13 2015-05-21 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
CN107208095B (zh) 2014-10-02 2021-11-16 阿布特斯生物制药公司 用于使乙型肝炎病毒基因表达沉默的组合物和方法
EP3034539A1 (en) * 2014-12-19 2016-06-22 Ethris GmbH Compositions for introducing nucleic acid into cells
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
WO2016178233A1 (en) 2015-05-05 2016-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
US20180208932A1 (en) 2015-07-29 2018-07-26 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis b virus gene expression
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US10010627B2 (en) 2016-06-03 2018-07-03 International Business Machines Corporation Modified polycationic polymers
US11506655B2 (en) 2016-07-29 2022-11-22 Streck, Inc. Suspension composition for hematology analysis control
MA45999A (fr) 2016-08-22 2019-06-26 Arbutus Biopharma Corp Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US11033572B2 (en) 2017-01-19 2021-06-15 Universiteit Gent Molecular adjuvants for enhanced cytosolic delivery of active agents
EP4512477A3 (en) 2017-04-22 2025-06-11 Immunomic Therapeutics, Inc. Improved lamp constructs
BR112019023014A2 (pt) 2017-05-02 2020-05-19 Immunomic Therapeutics Inc constructos de lamp aperfeiçoados compreendendo antígenos de câncer
EP3697209B1 (en) 2017-10-19 2024-07-24 Streck LLC Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
JP2021529173A (ja) 2018-06-20 2021-10-28 イエール ユニバーシティ Ｒｉｇ−ｉアゴニストおよびそれを使用した処置
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN121203032A (zh) 2019-10-18 2025-12-26 免疫治疗有限公司 包含癌抗原的改良lamp构建物
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
CN112237633B (zh) * 2020-10-22 2023-06-27 林君玉 一种pei/on复合物及其制备方法和用途
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
AU2022289260A1 (en) 2021-06-08 2023-12-07 Touchlight IP Limited Lentiviral vector
GB202108176D0 (en) 2021-06-08 2021-07-21 Touchlight Ip Ltd Vector
JP2025513022A (ja) 2022-04-10 2025-04-22 イミュノミック セラピューティックス， インコーポレイテッド 免疫応答増強遺伝子を含むバイシストロニックｌａｍｐ構築物およびその使用方法
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993020090A1 (en) * 1992-04-06 1993-10-14 University Of Medicine & Dentistry Of New Jersey Paired-ion oligonucleotides and methods for preparing same
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids

Also Published As

Publication number Publication date
US6013240A (en) 2000-01-11
FR2722506A1 (fr) 1996-01-19
FR2722506B1 (fr) 1996-08-14
DE69535540D1 (de) 2007-08-30
WO1996002655A1 (fr) 1996-02-01
NO970049D0 (no) 1997-01-07
JP4275728B2 (ja) 2009-06-10
AU2930795A (en) 1996-02-16
NO323110B1 (no) 2007-01-02
FI970115L (fi) 1997-01-10
FI119738B (fi) 2009-02-27
CA2194797A1 (fr) 1996-02-01
DK0770140T3 (da) 2007-11-19
NO970049L (no) 1997-01-07
EP0770140B1 (fr) 2007-07-18
CA2194797C (fr) 2010-03-23
IL114566A0 (en) 1995-11-27
ATE367448T1 (de) 2007-08-15
KR100424802B1 (ko) 2004-06-23
PT770140E (pt) 2007-10-19
JPH10502918A (ja) 1998-03-17
ZA955849B (en) 1996-02-21
DE69535540T9 (de) 2012-03-15
DE69535540T2 (de) 2008-06-19
EP0770140A1 (fr) 1997-05-02
FI970115A0 (fi) 1997-01-10
ES2290952T3 (es) 2008-02-16
IL114566A (en) 2005-08-31
KR970704889A (ko) 1997-09-06

Similar Documents

Publication Publication Date Title
MX9700270A (es) Composicion que contiene acidos nucleicos, preparacion y utilizacion.
MX9602561A (es) Composicion que contiene acidos nucleicos, su preparacion y sus usos.
BR9810369A (pt) Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
BR9810372A (pt) Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação
FI973363A0 (fi) Nukleiinihappoja sisältävä koostumus, sen valmistus ja käyttö
ES2181234T3 (es) Producto de combinacion que asocia un acido nucleico a una sustancia que desorganiza la matriz extracelular para la terapia genica.
HUP0100622A2 (hu) Nagy molekulatömegű észterolajokat tartalmazó hajkondicionáló készítmény
BG101103A (bg) Теломераза при бозайници
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
ATE308621T1 (de) Replizierende retrovirale konstrukte, ihre herstellung und verwendungen für den gentransfer
EP1189918A4 (en) ANTISENSE MODULATION OF INTEGRIN BETA 3 EXPRESSION
EP1123414A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF INTEGRIN ALPHA 4
ATE328074T1 (de) Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
BR0110111A (pt) Derivados de ácido poliamidanucléico, agentes e processos para a sua preparação
FI970696A7 (fi) Oligonukleotidikonjugaatit, koostumukset ja menetelmät ribonukleiiniha ppojen hajoittamiseksi
BR9712210A (pt) Processos de preparação de uma composição para a transferência de ácidos nucléicos e para a transferência de ácido nucléico em células in vitro ou ex vivo, e, composição para a transferência de ácidos nucléicos.
ES2188653T3 (es) Variantes de la dnasa i humana.
MX9703928A (es) Nuevos agentes de transfeccion y sus aplicaciones farmaceuticas.
ATE221895T1 (de) Chimäre oligonucleotide und ihre verwendung
UY24851A1 (es) Derivados de ácidos n-acil-alfa-aminados